Third member of US FDA advisory panel resigns over Alzheimer’s drug approval

Source: Fox Business

“A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so. Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel. … On Tuesday, a member of the advisory group who voted against the approval, Washington University neurologist Dr. Joel Perlmutter, resigned from the committee, citing the FDA’s approval of Aduhelm. Mayo Clinic neurologist Dr. David Knopman said he resigned on Wednesday. The 11-member committee voted nearly unanimously in November that Biogen’s drug should not be approved, citing inconclusive evidence that the drug was effective.” (06/11/21)

https://www.foxbusiness.com/lifestyle/third-member-of-us-fda-advisory-panel-resigns-over-alzheimers-drug-approval